SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-292104
Filing Date
2021-10-05
Accepted
2021-10-05 16:20:03
Documents
12
Period of Report
2021-10-05
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d180484d8k.htm   iXBRL 8-K 35904
  Complete submission text file 0001193125-21-292104.txt   165444

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA xers-20211005.xsd EX-101.SCH 2901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE xers-20211005_lab.xml EX-101.LAB 18888
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xers-20211005_pre.xml EX-101.PRE 11866
5 EXTRACTED XBRL INSTANCE DOCUMENT d180484d8k_htm.xml XML 3529
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 211306885
SIC: 2834 Pharmaceutical Preparations